title: [Successful salvage therapy of continuous low-dose irinotecan for a patient with relapsed and refractory diffuse large B-cell lymphoma].
abstract: A 46-year-old man with relapsed and refractory diffuse large B-cell lymphoma after salvage therapy (EPOCH and ESHAP regimens) was treated with continuous low-dose CPT-11 (irinotecan hydrochloride) at 30 mg/day (20 mg/m2/day) for three consecutive days every week. The patient's general condition and both LDH and CRP, tumor related markers, improved dramatically. Complete remission was achieved after a 10-week cycle of therapy without severe adverse effects. Unfortunately, the lymphoma relapsed after allogeneic hematopoietic stem cell transplantation, low-dose CPT-11 therapy was used again to palliate tumor symptoms for 12 months. This therapy may be a useful salvage and palliative chemotherapy for relapsed and refractory lymphoma.
authors.affiliation: Hematology and Immunology, Kanazawa Medical University.
authors.forename: Yasufumi
authors.initials: Y
authors.lastname: Masaki
authors.forename: Toshioki
authors.initials: T
authors.lastname: Sawaki
authors.forename: Kumiko
authors.initials: K
authors.lastname: Shimoyama
authors.forename: Hiromi
authors.initials: H
authors.lastname: Karasawa
authors.forename: Takafumi
authors.initials: T
authors.lastname: Kawanami
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Fukushima
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kawabata
authors.forename: Noriyoshi
authors.initials: N
authors.lastname: Ogawa
authors.forename: Yuji
authors.initials: Y
authors.lastname: Wano
authors.forename: Susumu
authors.initials: S
authors.lastname: Sugai
authors.forename: Yuko
authors.initials: Y
authors.lastname: Hirose
authors.forename: Hisanori
authors.initials: H
authors.lastname: Umehara
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003131:Combined Modality Therapy; D006801:Humans; D000077146:Irinotecan; D016393:Lymphoma, B-Cell / Q000628:therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010166:Palliative Care; D012074:Remission Induction; D016879:Salvage Therapy; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D000077146:Irinotecan; D002166:Camptothecin